Tecentriq Hybreza: payments to doctors
Payments that named Tecentriq Hybreza as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $42K
- Providers
- 1,560
- Transactions
- 1,885
- Average per transaction
- $22
The per-transaction average — $22 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,560 providers the average total is $27, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $40,118 | 95.6% |
| Genentech, Inc. | $1,862 | 4.4% |